Treatment-resistant Schizophrenia
📧 Sign up to get email alerts when something new happens for Treatment-resistant Schizophrenia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-02-11Clinical Trial Update: Effectiveness of Exercise Alone and tDCS+Exercise on Cognitive Function Improvement in Patients With Treatment Resistant Schizophrenia [NA]
A clinical trial evaluating whether exercise alone and transcranial direct current stimulation plus exercise can improve cognitive function …
-
CLINICAL_TRIALS research · 2026-02-06Clinical Trial Update: Τhe Combination of Pharmacotherapy With RECOVERYTRSGR and RECOVERYTRSBDGR. [Phase 4]
Phase 4 clinical trial evaluating the combination of RECOVERYTRSGR and RECOVERYTRSBDGR for treatment-resistant schizophrenia and treatment-r…
-
CLINICAL_TRIALS research · 2026-02-03Clinical Trial Update: Maintenance ElectroConvulsive Therapy in Clozapine RESISTant Schizophrenia - the MECT-RESIST Trial [NA]
A clinical trial evaluating maintenance electroconvulsive therapy for clozapine-resistant schizophrenia, with recruitment ongoing.
-
CLINICAL_TRIALS trial_result · 2025-03-06Clinical Trial Update: Neural Biomarkers of Clozapine Response
A completed clinical trial from the University of Pittsburgh examining neural biomarkers associated with clozapine response in schizophrenia…
-
CLINICAL_TRIALS research · 2024-07-17Clinical Trial Update: Effect of Atenolol Versus Ivabradine on HRV in TRS Patients on Clozapine With Tachycardia: A Randomised Control Trial. [NA]
A randomized trial is comparing atenolol versus ivabradine to assess their effect on heart rate variability in treatment-resistant schizophr…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-09-29Clinical Trial Update: Multidisciplinary Design to Optimize Schizophrenia Treatment Based on Multi-omics Data and Systems Biology Analysis [Phase 4]
Phase 4 clinical trial update exploring multidisciplinary design to optimize schizophrenia treatment using multi-omics data and systems biol…
-
CLINICAL_TRIALS trial_result · 2023-07-20Clinical Trial Update: Add-on Aripiprazole on Cardiometabolic Profile in Treatment Resistant Schizophrenia: RCT [Phase 4]
Phase 4 clinical trial evaluating add-on aripiprazole and its effect on cardiometabolic risk in treatment-resistant schizophrenia.
-
CLINICAL_TRIALS trial_result · 2022-03-02Clinical Trial Update: Telmisartan Pilot Study on Treatment Resistant Schizophrenia [Phase 2]
Phase 2 pilot study on telmisartan for treatment-resistant schizophrenia was terminated with posted results.
-
FDA approval · 2021-07-29FDA Approved: CLOZAPINE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved a supplemental application for CLOZAPINE submitted by Teva Pharmaceuticals USA, Inc.
-
CLINICAL_TRIALS trial_result · 2021-06-16Clinical Trial Update: Comparison of Maintenance ECT Versus Clozapine in Treatment-resistant Schizophrenia [Phase 4]
Phase 4 clinical trial comparing maintenance electroconvulsive therapy versus clozapine in treatment-resistant schizophrenia has completed.
-
CLINICAL_TRIALS trial_result · 2020-08-27Clinical Trial Update: SMART Design to Compare Antipsychotic Treatments in Treatment-Resistant Schizophrenia [Phase 3]
Phase 3 trial design update comparing antipsychotic treatments for treatment-resistant schizophrenia; status and full results are not provid…
-
CLINICAL_TRIALS trial_result · 2020-01-07Clinical Trial Update: Efficacy of Lu AF35700 in Patients With Early-in-disease or Late-in-disease Treatment-resistant Schizophrenia [Phase 3]
Phase 3 trial of Lu AF35700 in treatment-resistant schizophrenia was terminated; results were posted in 2020.
-
FDA approval · 2019-01-16FDA Approved: CLOZAPINE — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approved a supplemental application to authorize a generic version of Clozapine manufactured by Mylan Pharmaceuticals Inc.
-
FDA approval · 2017-02-23FDA Approved: CLOZARIL — Supplemental Application (HLS Therapeutics (USA), Inc.)
The FDA approved a supplemental application for Clozaril (clozapine) submitted by HLS Therapeutics (USA), Inc., resulting in changes to its …
-
FDA approval · 2015-09-18FDA Approved: CLOZARIL — Supplemental Application (HLS Therapeutics (USA), Inc.)
FDA approved a supplemental application for CLOZARIL (clozapine) submitted by HLS Therapeutics (USA), Inc., signaling an update to the produ…
-
FDA approval · 2014-03-25FDA Approved: VERSACLOZ — Supplemental Application (TruPharma LLC)
FDA approved a supplemental application for VERSACLOZ (clozapine) from TruPharma LLC, updating the labeling per the supplemental filing.
-
CLINICAL_TRIALS trial_result · 2013-10-29Clinical Trial Update: GlyT-1 Inhibitor Treatment for Refractory Schizophrenia [Phase 2]
Phase 2 clinical trial update reporting completion of testing for a GlyT-1 inhibitor in treatment-refractory schizophrenia.